EGFR and non-small cell lung carcinoma: The phase III IMPRESS trial aimed to evaluate the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib.